How much revenue did Celyad Oncology generate this year?
Celyad Oncology has achieved a revenue of 62.5 M EUR this year.
Celyad Oncology Revenue 2024
Celyad Oncology Revenue
62.5 M EUR
Ticker
CYAD.BR
ISIN
BE0974260896
WKN
A1W7Q9
In 2024, Celyad Oncology's sales reached 62.5 M EUR, a 61,174.51% difference from the 102,000 EUR sales recorded in the previous year.
The Celyad Oncology Revenue history
| YEAR | REVENUE (undefined EUR) | GROSS MARGIN (%) |
|---|---|---|
| 2025e | 156.25 | 0,02 |
| 2024e | 62.5 | 0,05 |
| 2023 | 0.1 | 32,35 |
| 2022 | - | - |
| 2021 | - | - |
| 2020 | 0.01 | 100,00 |
| 2019 | 0.01 | 100,00 |
| 2018 | 3.12 | 100,00 |
| 2017 | 3.54 | 85,45 |
| 2016 | 8.52 | 99,38 |
| 2015 | 0 | 66,67 |
| 2014 | 0.15 | -8407,53 |
| 2013 | - | - |
| 2012 | 0.05 | -11320,00 |
| 2011 | - | - |
| 2010 | 1.52 | -109,87 |
Celyad Oncology Revenue, EBIT, Net Income BE0974260896 · A1W7Q9
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Celyad Oncology, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Celyad Oncology from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Celyad Oncology’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Celyad Oncology. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Celyad Oncology’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Celyad Oncology’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Celyad Oncology’s growth potential.
Celyad Oncology Revenue, EBIT and net profit per share
| Date | Celyad Oncology Revenue | Celyad Oncology EBIT | Celyad Oncology Net Income |
|---|---|---|---|
| 2025e | 156.25 M undefined | -13.81 M undefined | 15.41 M undefined |
| 2024e | 62.5 M undefined | -10.67 M undefined | 20.21 M undefined |
| 2023 | 102,000 undefined | -9.54 M undefined | -8.45 M undefined |
| 2022 | 0 undefined | -5.77 M undefined | -40.94 M undefined |
| 2021 | 0 undefined | -26.39 M undefined | -26.51 M undefined |
| 2020 | 5,000 undefined | -16.98 M undefined | -17.2 M undefined |
| 2019 | 6,000 undefined | -28.88 M undefined | -28.63 M undefined |
| 2018 | 3.12 M undefined | -37.99 M undefined | -37.43 M undefined |
| 2017 | 3.54 M undefined | -26.6 M undefined | -56.4 M undefined |
| 2016 | 8.52 M undefined | -25.61 M undefined | -23.61 M undefined |
| 2015 | 3,000 undefined | -29.67 M undefined | -29.11 M undefined |
| 2014 | 146,000 undefined | -16.44 M undefined | -16.45 M undefined |
| 2013 | 0 undefined | -12.95 M undefined | -14.49 M undefined |
| 2012 | 50,000 undefined | -12.9 M undefined | -13.52 M undefined |
| 2011 | 0 undefined | -9.3 M undefined | -9.35 M undefined |
| 2010 | 1.52 M undefined | -6.42 M undefined | -6.71 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2010 | 1.52 M EUR | -6.42 M EUR | -6.71 M EUR |
| 2011 | 0 EUR | -9.3 M EUR | -9.35 M EUR |
| 2012 | 50,000 EUR | -12.9 M EUR | -13.52 M EUR |
| 2013 | 0 EUR | -12.95 M EUR | -14.49 M EUR |
| 2014 | 146,000 EUR | -16.44 M EUR | -16.45 M EUR |
| 2015 | 3,000 EUR | -29.67 M EUR | -29.11 M EUR |
| 2016 | 8.52 M EUR | -25.61 M EUR | -23.61 M EUR |
| 2017 | 3.54 M EUR | -26.6 M EUR | -56.4 M EUR |
| 2018 | 3.12 M EUR | -37.99 M EUR | -37.43 M EUR |
| 2019 | 6,000 EUR | -28.88 M EUR | -28.63 M EUR |
| 2020 | 5,000 EUR | -16.98 M EUR | -17.2 M EUR |
| 2021 | 0 EUR | -26.39 M EUR | -26.51 M EUR |
| 2022 | 0 EUR | -5.77 M EUR | -40.94 M EUR |
| 2023 | 102,000 EUR | -9.54 M EUR | -8.45 M EUR |
| 2024e | 62.5 M EUR | -10.67 M EUR | 20.21 M EUR |
| 2025e | 156.25 M EUR | -13.81 M EUR | 15.41 M EUR |
Celyad Oncology stock margins BE0974260896 · A1W7Q9
The Celyad Oncology margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Celyad Oncology. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Celyad Oncology.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Celyad Oncology's sales revenue. A higher gross margin percentage indicates that the Celyad Oncology retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Celyad Oncology's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Celyad Oncology's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Celyad Oncology's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Celyad Oncology. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Celyad Oncology's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Celyad Oncology Margin History
| Celyad Oncology Gross margin | Celyad Oncology Profit margin | Celyad Oncology EBIT margin | Celyad Oncology Profit margin |
|---|---|---|---|
| 2025e | 32.35 % | -8.84 % | 9.86 % |
| 2024e | 32.35 % | -17.08 % | 32.34 % |
| 2023 | 32.35 % | -9,356.86 % | -8,282.35 % |
| 2022 | 32.35 % | 0 % | 0 % |
| 2021 | 32.35 % | 0 % | 0 % |
| 2020 | 100 % | -339,540 % | -344,080.03 % |
| 2019 | 100 % | -481,316.65 % | -477,200 % |
| 2018 | 100 % | -1,219.52 % | -1,201.51 % |
| 2017 | 85.45 % | -751.5 % | -1,593.08 % |
| 2016 | 99.38 % | -300.47 % | -276.97 % |
| 2015 | 66.67 % | -989,066.7 % | -970,466.7 % |
| 2014 | -8,407.53 % | -11,258.22 % | -11,269.18 % |
| 2013 | 32.35 % | 0 % | 0 % |
| 2012 | -11,320 % | -25,800 % | -27,040 % |
| 2011 | 32.35 % | 0 % | 0 % |
| 2010 | -109.87 % | -422.37 % | -441.45 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2010 | -109.87 % | -422.37 % | -441.45 % |
| 2011 | 32.35 % | 0 % | 0 % |
| 2012 | -11,320 % | -25,800 % | -27,040 % |
| 2013 | 32.35 % | 0 % | 0 % |
| 2014 | -8,407.53 % | -11,258.22 % | -11,269.18 % |
| 2015 | 66.67 % | -989,066.7 % | -970,466.7 % |
| 2016 | 99.38 % | -300.47 % | -276.97 % |
| 2017 | 85.45 % | -751.5 % | -1,593.08 % |
| 2018 | 100 % | -1,219.52 % | -1,201.51 % |
| 2019 | 100 % | -481,316.65 % | -477,200 % |
| 2020 | 100 % | -339,540 % | -344,080.03 % |
| 2021 | 32.35 % | 0 % | 0 % |
| 2022 | 32.35 % | 0 % | 0 % |
| 2023 | 32.35 % | -9,356.86 % | -8,282.35 % |
| 2024e | 32.35 % | -17.08 % | 32.34 % |
| 2025e | 32.35 % | -8.84 % | 9.86 % |
Celyad Oncology Aktienanalyse
What does Celyad Oncology do?
Celyad Oncology is a biotech company specializing in the discovery and development of new cancer immunotherapies. The company, headquartered in Mont-Saint-Guibert, Belgium, was founded in 2007 and has been listed on the NASDAQ and Euronext stock exchanges since September 2015. The history of Celyad Oncology began with the discovery of CAR-T therapy, which is based on the tumor cell recognition by T cells of the body's immune system. In 2001, researchers at the University of Leuven (Belgium) introduced a new method for culturing T cells, which was a major step in the development of CAR-T therapy. In 2004, the researchers founded Celyad with the aim of developing clinically effective CAR-T therapies. In 2015, the company was renamed Celyad Oncology to emphasize its strategic focus on oncology products. Celyad Oncology has developed a unique business model that focuses on the clinical development of CAR-T cell therapies. The company uses innovative technologies such as allogeneic CAR-T cells, which come from donor tissue from persons other than the patient. These cells have the advantage of being able to be produced in unlimited quantities, enabling the rapid and cost-effective manufacturing of CAR-T cells. In addition, the company has developed a platform technology called "shRNA" that regulates gene expression in T cells, thereby improving the safety and efficacy of CAR-T therapies. The company is divided into various divisions, from preclinical research to the clinical development and commercialization of CAR-T therapies. Celyad Oncology has several product candidates in various stages of development, focusing on indications such as multiple myeloma, acute myeloid leukemia (AML), and solid tumors. One of Celyad Oncology's most promising product candidates is CYAD-01, a CAR-T cell product targeting the CD19 protein. It is currently in a Phase I/IIa clinical trial evaluating the safety and efficacy of CYAD-01 in patients with refractory or relapsed CD19+ B-cell lymphoma. In October 2020, the product candidate achieved a complete response in a patient with a different indication, acute myeloid leukemia (AML). Another product candidate is CYAD-101, an allogeneic CAR-T cell product targeting the NKG2D protein. This protein is overexpressed on many cancer cells but not on healthy cells. CYAD-101 is currently in a Phase I/II clinical trial for the treatment of various tumor types, including lung cancer and pancreatic cancer. Celyad Oncology also collaborates with other companies to further develop its technologies and product candidates. In 2018, the company entered into a partnership with Novartis to utilize Celyad Oncology's CAR-T platform technology for the development of products for solid tumors. In 2019, Celyad Oncology announced a partnership with ONO Pharmaceutical to accelerate the development of CYAD-211, an allogeneic CAR-T cell product for the treatment of multiple myeloma. In summary, Celyad Oncology has not only a unique business model but also promising product candidates and technologies that have the potential to revolutionize the treatment of cancer. With a strong pipeline and targeted clinical development, Celyad Oncology is well positioned to continue its success in the future. Celyad Oncology ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Celyad Oncology's Sales Figures
The sales figures of Celyad Oncology originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Celyad Oncology’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Celyad Oncology's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Celyad Oncology’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Celyad Oncology Stock
How much was the turnover of the company Celyad Oncology compared to the previous year?
The revenue of Celyad Oncology has increased by 61,174.51% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Celyad Oncology?
The revenue of Celyad Oncology is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Celyad Oncology measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Celyad Oncology so important for investors?
The revenue of Celyad Oncology is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Celyad Oncology pay?
Over the past 12 months, Celyad Oncology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Celyad Oncology is expected to pay a dividend of 0 EUR.
What is the dividend yield of Celyad Oncology?
The current dividend yield of Celyad Oncology is .
When does Celyad Oncology pay dividends?
Celyad Oncology pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Celyad Oncology?
Celyad Oncology paid dividends every year for the past 0 years.
What is the dividend of Celyad Oncology?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Celyad Oncology located?
Celyad Oncology is assigned to the 'Health' sector.
Wann musste ich die Aktien von Celyad Oncology kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Celyad Oncology from 7/3/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 7/3/2024.
When did Celyad Oncology pay the last dividend?
The last dividend was paid out on 7/3/2024.
What was the dividend of Celyad Oncology in the year 2023?
In the year 2023, Celyad Oncology distributed 0 EUR as dividends.
In which currency does Celyad Oncology pay out the dividend?
The dividends of Celyad Oncology are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Celyad Oncology
Our stock analysis for Celyad Oncology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Celyad Oncology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Celyad Oncology Revenue
- Celyad Oncology Net Income
- Celyad Oncology P/E
- Celyad Oncology P/S
- Celyad Oncology EBIT
- Celyad Oncology Dividend
- Celyad Oncology Stocks
- Celyad Oncology Market capitalization
- Celyad Oncology Debt
- Celyad Oncology Liabilities
- Celyad Oncology Equity
- Celyad Oncology AAQS
- Celyad Oncology Employees
- Celyad Oncology ROE
- Celyad Oncology ROA
- Celyad Oncology ROCE
